All patients were pretreated with aspirin (100 mg daily) and ticlopidine (200 mg daily)/clopidogrel (75 mg daily). Aspirin and ticlopidine/clopidogrel treatment was recommended for at least 8 months. The procedures were performed according to the standard clinical guidelines. In all cases, the interventional strategy and the use of adjunctive devices and pharmacotherapy were at the discretion of Background-There are currently inadequate data about whether late restenosis occurs after drug-eluting stent (DES) implantation in patients with DES restenosis. Methods and Results-We collected data for 608 patients who received revascularization for DES restenosis between 2004 and 2012 and analyzed 688 lesions: 359 lesions treated with a first-generation DES (first DES) and 329 lesions treated with a second-generation DES (second DES). Two serial angiographic follow-ups were routinely planned for the patients (at 8 and 20 months after the procedure). Early follow-up angiography was performed for 620 lesions (90.1%), and recurrent restenosis occurred in 84 lesions (25.8%) in the first DES group and in 72 lesions (24.5%) in the second DES group (P=0.78). Target lesion revascularization was performed for 69 lesions (21.2%) in the first DES group and for 48 lesions (16.3%) in the second DES group (P=0.15). Late follow-up angiography was performed for 438 (87.1%) of the remaining 503 lesions (excluding target lesion revascularization lesions), and late restenosis was found in 35 lesions (15.8%) in the first DES group and in 28 lesions (14.7%) in the second DES group (P=0.79). Nonfocal-type restenosis, percentage diameter stenosis after the procedure, previous stent size ≤2.5 mm, and right coronary artery ostial lesion were independent predictors of early restenosis. Nonfocal-type restenosis, percentage diameter stenosis at early follow-up, and stent fracture were independent predictors of late restenosis. Conclusions-Late restenosis occurs after both first DES implantation and second DES implantation for DES restenosis. (Circ Cardiovasc Interv. 2016;9:e004449.
M anagement of drug-eluting stent (DES) restenosis is challenging, and the best therapeutic strategy remains unclear. In recent guideline, both DES and paclitaxel-coated balloon (PCB) are equally recommended for patients with DES restenosis. 1 Nowadays, PCB angioplasty has emerged as a potential alternative to the current treatment for DES restenosis [2] [3] [4] because PCB has the advantage of avoiding a new stent layer. However, a recent study has shown that late restenosis occurs after PCB angioplasty for DES restenosis lesions. 5 Another study has shown that a second-generation DES (second DES) implantation for patients with DES restenosis provides superior results to those obtained with PCB. 6 There are currently inadequate data about the long-term efficacy and safety of DES implantation for DES restenosis lesions. To evaluate the long-term safety and efficacy of DES implantation, we investigated serial clinical and angiographic outcomes of the first-generation DES (first DES) and second DES implantations in patients with DES restenosis.
Methods

Patient Population
Prospectively collected data for patients who underwent revascularization for DES restenosis at Kurashiki Central Hospital were retrospectively analyzed. Between 2004 and 2012, 688 DES restenosis lesions (608 patients) were treated with a DES: 359 lesions treated with the first DES and 329 lesions treated with the second DES. The exclusion criteria were lesions located in bypass conduits and bailout stenting after PCB angioplasty. The study was performed in accordance with the provisions of the Declaration of Helsinki and local regulations. All patients provided informed consent for both the procedure and subsequent data collection and analysis for research purposes, and the study was approved by the Institutional Ethics Committee.
Follow-Up and Definitions
Two serial angiographic follow-ups were routinely planned for the patients. Early follow-up was planned at 8 months after the procedure, and late follow-up was planned at 20 months after the procedure. The follow-up angiogram was obtained earlier if clinically indicated. Follow-up angiography performed at 6 to 12 months was considered early follow-up, and follow-up angiography performed at 12 to 24 months was considered late follow-up. When recurrent restenosis occurred within 6 months, it was included in early follow-up results. Clinical follow-up was performed by telephone contact or office visit. Binary restenosis at follow-up was defined as stenosis occupying ≥50% of the diameter. Late restenosis was defined as diameter stenosis ≥50% at late follow-up in lesions of <50% diameter stenosis at early follow-up. Target lesion revascularization (TLR) was defined as any repeat percutaneous coronary intervention or coronary artery bypass surgery with either of the following: (1) symptoms of ischemia or objective signs of ischemia and angiographic diameter stenosis of ≥50%, or (2) angiographic diameter stenosis of ≥70% without symptoms of ischemia or objective signs of ischemia. Stent thrombosis was defined according to the Academic Research Consortium guidelines. 7 Stent fracture was defined as the complete separation of stent segments or stent struts confirmed at the use of a repeat DES and evaluated through multiple projections. To assess the interobserver variability, the angiographic diagnosis of stent fracture required an independent view and the agreement of 2 independent cardiologists (S.H. and K.K.) who were blinded to the clinical and procedural data.
Angiographic Analysis
Quantitative coronary angiographic analysis was performed using QCA-CMS (Medis Medical Imaging Systems, Leiden, The Netherlands). All angiograms were analyzed in a random sequence by 2 experienced observers who were blinded to the clinical characteristics of patients. Coronary angiograms were obtained in multiple views after intracoronary nitrate administration. Reference diameter, minimal lumen diameter, percentage diameter stenosis, and lesion length were measured before and after intervention and at followup. Acute gain was defined as minimal lumen diameter immediately after the procedure minus that at baseline. Late lumen loss was defined as minimal lumen diameter immediately after the procedure minus that at angiographic follow-up. Delayed late lumen loss was defined as minimal lumen diameter at early follow-up minus that at late follow-up. Measurements were done at the target lesion treated by DES implantation within 5 mm proximal and distal to the treated area. In-stent restenosis was classified according to the Mehran classification. 8 A multifocal lesion was classified as nonfocal-type restenosis lesion. Stent fracture was angiographically defined at the use of a repeat DES.
Study End Points
The efficacy end points included late lumen loss, rate of binary restenosis, and rate of TLR at follow-up. The safety end points included major adverse cardiac events and a composite of cardiac death, myocardial infarction, or stent thrombosis at follow-up. The efficacy end points were evaluated on a per-lesion basis, and the safety end points were evaluated on a per-patient basis.
Statistical Analysis
Continuous variables are expressed as mean±SD or as median (interquartile range). Values are shown as numbers with relative percentage or SD. For continuous data, the groups were compared with the t test or Wilcoxon rank-sum test based on the distribution. Categorical variables were compared using the χ 2 test. Risk factors of early restenosis and late restenosis after DES implantation were analyzed separately. A multivariable logistic regression model instead of a Cox proportional hazard model was used to identify independent risk factors of early and late restenosis because restenosis is well known to be a time-related phenomenon, and the time at which restenosis is detected can be highly influenced by physicians' and patients' decisions. Stepwise multivariable logistic regression analysis was then applied to individuate the variables independently associated with recurrent restenosis. The variables used in the multivariable analyses were selected when they were shown to affect dependent variables with a P value <0.05 in univariate analysis. Independent variables are expressed as odds ratios with 95% confidence intervals. P values of <0.05 were considered to be statistically significant. JMP 9 (SAS Institute Inc, Cary, NC) was used for all statistical calculations. Table 1 shows baseline clinical, angiographic, and procedural characteristics in the first DES and second DES groups. Among the lesions, 67.4% of the lesions (n=464) originally received a sirolimus-eluting stent, 17.2% (n=118) received a paclitaxel-eluting stent, 3.2% (n=22) received a zotarolimus-eluting stent, 7.7% (n=53) received a cobalt-chromium everolimus-eluting stent, and 4.5% (n=31) received a biolimus-eluting stent. In the first DES group, 181 (50.4%) of the lesions were treated by a sirolimus-eluting stent, 161 (44.9%) were treated by a paclitaxel-eluting stent, and 17 (4.7%) were treated by a zotarolimus-eluting stent. In the second DES group, 213 (64.7%) of the lesions were treated by a cobaltchromium everolimus-eluting stent, 80 (24.3%) were treated by a biolimus-eluting stent, 31 (9.4%) were treated by a platinum-chromium everolimus-eluting stent, and 5 (1.5%) were treated by a resolute zotarolimus-eluting stent.
Results
Baseline and Procedural Data
No significant differences were found in clinical characteristics between the 2 groups except for diabetes mellitus. Bifurcation lesions were more frequent in the second DES group. Reference diameter (2.99±0.49 versus 3.03±0.52 mm, P=0.37) before the procedure was similar in the first DES and second DES groups. Percentage diameter stenosis before the procedure was smaller in the first DES group (69.9±17.0% versus 73.1±17.5%, P=0.01). Lesion length in the second DES group was significantly longer than that in the first DES group (14.5±9.9 versus 17.4±12.9 mm, P<0.001). Acute gain was similar in the 2 groups (1.76±0.64 versus 1.83±0.69 mm, P=0.26).
WHAT IS KNOWN
• Drug-eluting stent (DES) implantation is recommended for DES restenosis in recent guidelines.
• There are currently inadequate data about the longterm efficacy and safety of DES implantation for DES restenosis lesions.
• Whether late restenosis occurs after DES implantation for DES restenosis is unknown.
WHAT THE STUDY ADDS
• Late restenosis occurs even after the second DES implantation for DES restenosis lesions.
• Nonfocal-type restenosis is associated with restenosis risk in both early and late phases. Figure 2A shows changes in percentage diameter stenosis in the 2 groups. Percentage diameter stenosis at early follow-up and late follow-up was similar in the 2 groups. Figure 2B shows the cumulative frequency distribution of delayed late lumen loss. Figure 3 shows angiographic outcomes by restenosis type (focal-versus nonfocal-type lesions) in the first DES and second DES groups. In the first DES group, recurrent restenosis occurred in 16.9% of focal restenosis lesions and in 37.1% of nonfocal restenosis lesions (P<0.001). Late lumen loss was smaller in focal restenosis lesions than in nonfocal restenosis lesions (0.57±0.62 versus 0.87±0.85 mm, P<0.001; median, 0.46 versus 0.74 mm). In the first DES group, late restenosis occurred in 9.2% of focal restenosis lesions and in 24.7% of nonfocal restenosis lesions (P=0.002). Delayed late lumen loss was smaller in focal restenosis lesions than in nonfocal restenosis lesions (0.14±0.46 versus 0.35±0.61 mm, P=0.005; median, 0.09 versus 0.22 mm). In the second DES group, recurrent restenosis occurred in 18.0% of focal restenosis lesions and in 31.9% of nonfocal restenosis lesions (P=0.007). Late lumen loss was smaller in focal restenosis lesions than in nonfocal restenosis lesions (0.49±0.71 versus 0.70±0.79 mm, P=0.01; median, 0.36 versus 0.55 mm). In the second DES group, late restenosis occurred in 8.9% of focal restenosis lesions and in 19.2% of nonfocal restenosis lesions (P=0.04). Delayed late lumen loss was similar in the 2 restenosis group (0.25±0.44 versus 0.34±0.59 mm, P=0.22; median, 0.20 versus 0.22 mm).
In the second DES group, 78.4% of the lesions originally received a first DES and 21.6% received a second DES. Recurrent restenosis occurred in 20.1% of the lesions that originally received a first DES and in 40.0% of the lesions that originally received a second DES (P=0.002). Late restenosis occurred in 12.8% of the lesions that originally received a first DES and in 23.5% of the lesions that originally received a second DES (P=0.12).
Clinical Outcomes
Clinical follow-up at 20 months was performed for 657 lesions (95.5%). There was only 1 case of stent thrombosis in the second DES group, and there were 2 cases of stent thrombosis in the first DES group. The cumulative incidences of TLR, major adverse cardiac events, and a composite of cardiac death, myocardial infarction, or stent thrombosis are shown in Figure 4 . The rates of TLR during 24-month follow-up in the first DES and second DES groups were 28.1% and 21.5%, respectively (logrank P=0.051). Among 160 patients who had undergone TLR, 31 lesions were treated with balloon angioplasty, 42 lesions were treated with DES, 78 lesions were treated with PCB, and 9 lesions needed coronary artery bypass surgery. Among early TLR lesions, 9.4% were for acute coronary syndrome, 25.6% were for effort angina, and 65.0% were for severe restenosis at follow-up angiography with objective signs of ischemia. Among late TLR lesions, 11.6% were for acute coronary syndrome, 23.3% were for effort angina, and 65.1% were for severe restenosis at follow-up angiography with objective signs of ischemia. The rates of major adverse cardiac events during 24-month follow-up in the first DES and second DES groups were 31.6% and 25.7%, respectively (log-rank P=0. 14) . The rates of a composite of cardiac death, myocardial infarction, or target lesion thrombosis during 24-month follow-up in the first DES and second DES groups were 4.8% and 2.3%, respectively (log-rank P=0.36). Table 3 shows baseline characteristics of lesions with and those without recurrent restenosis during 24-month follow-up. 
Predictors of Recurrent Restenosis
Discussion
In this study, we analyzed the long-term safety and efficacy of the first DES and second DES implantations in patients with DES restenosis. Our results suggest that late restenosis occurs after both first DES implantation and second DES implantation for DES restenosis and that risk factors of recurrent restenosis after DES implantation for DES restenosis vary depending on the period of time after the procedure.
There are concerns about the first DESs with regard to late restenosis or stent thrombosis, especially at the late phase. 9 Second DESs with biocompatible and biodegradable polymers and with improved drug kinetics have been designed to overcome the limitations of the first DESs. Despite these advances, a recent study demonstrated similar prevalences of neoatherosclerosis in lesions that received the first DES implantation and lesions that received the second DES implantation. 10 Late restenosis after DES implantation was reported for de novo coronary lesions, 9, 11 even after the second DES implantation. 12 The 3-year follow-up of the RIBS-V trial 13 (Restenosis Intra-Stent of Bare Metal Stents: Paclitaxel-Eluting Balloon vs Everolimus-Eluting Stent; 189 patients) showed superior angiographic outcome of the second DES implantation over treatment with a PCB, and the rate of late TLR was very low. However, types of in-stent restenosis (bare-metal stent restenosis or DES restenosis) had different biological responses after DES implantation. It was previously reported that outcomes after DES implantation are worse in patients with DES restenosis than in those with baremetal stent restenosis. 14, 15 The ISAR-DESIRE 3 trial 16 (Efficacy Study of Paclitaxel-Eluting Balloon, Stent vs Plain Angioplasty for Drug-Eluting Stent Restenosis; 402 patients) demonstrated the existence of late TLR. The trial showed that late TLR occurred after both PCB angioplasty and first DES implantation for treatment of DES restenosis. Our results for the first DES group are consistent with the results of that trial. There are currently no data from serial clinical and angiographic followup to support the second DES implantation for treatment of Table 3 DES restenosis. In this study, a statistically significant reduction in recurrent restenosis in the second DES group than that in the first DES group was not seen in the early follow-up or late follow-up. In the second DES group, the lesions that originally received a second DES showed worse angiographic outcomes than the lesions that originally received a first DES. The results indicate that DES failure after the second DES implantation for DES restenosis might increase because the second DES has been used widely. Our previous study showed that late restenosis occurs after PCB angioplasty for DES restenosis lesions. 5 The [17] [18] [19] The mechanisms of DES restenosis might be related to late restenosis. In this study, right coronary artery ostial lesion was an independent predictor of early restenosis. Right coronary artery ostial lesion is associated with a high restenosis rate after DES implantation. 20 Muscle bundles of the right coronary artery orifice cause chronic stent recoil and excessive intimal growth. The mechanical stress was speculated to be one of the mechanisms of restenosis after stenting of the right coronary artery ostial lesion. Percentage diameter stenosis after the procedure was also an independent predictor of early restenosis. This may be in part a result of underexpansion of a stent because of artery recoil or neointimal hyperplasia. Stent underexpansion seems to be a significant cause of restenosis after DES implantation treatment for in-stent restenosis. 21 Obtaining a high acute gain might be essential for minimizing the risk of recurrent restenosis in patients treated with a DES for DES restenosis.
. Baseline Characteristics Among Lesions With and Without Recurrent Restenosis During a 24-Month Follow-Up Period
In this study, stent fracture was found to be an independent predictor of late restenosis. Stent fracture has been observed in a relatively large number of lesions after DES implantation. [22] [23] [24] Several studies have demonstrated that stent fracture was associated with risk for restenosis, TLR, and major adverse cardiac events. [22] [23] [24] Mechanical fatigue of the stent may occur because of vessel stress such as compression, torsion, kinking, elongation, bending, and shear stress during cardiac contraction. 25 Stent fracture causes local mechanical stimulation of the vessel wall, inducing inflammation, which results in a higher risk of restenosis. Another DES implantation for DES restenosis with stent fracture is a controversial strategy, because of the possible recurrence of stent fracture. The recurrence of stent fracture may cause local mechanical stimulation of the vessel wall, inducing inflammation, which results in late restenosis.
Nonfocal-type restenosis was found to be an independent predictor of early restenosis and late restenosis. It has been suggested in some reports that focal DES restenosis may be related to mechanical or technical factors such as stent fracture, localized imperfect drug elution, and polymer disruption, whereas nonfocal DES restenosis may be related to drug failure. 26, 27 Repeat stenting may lead to an uneven distribution of drug release and suboptimal stent geometry. 28 Moreover, multiple stent layers with a long length may not enable maintenance of the original anatomy of the arteries. Repeat stenting has a serial problem of the next treatment of recurrent restenosis being limited because of multiple layers of metal in the coronary artery. In our previous study, PCB angioplasty showed significantly better angiographic outcomes than did repeat DES implantation in nonfocal-type restenosis lesions. 29 The use of a PCB may be more favorable in nonfocal-type lesions, in which multiple stent layers with a long length should be avoided.
Study Limitations
This study has several limitations. First, this was a retrospective single-center study with observational analysis. However, the results of this study are valuable because we included all consecutive patients undergoing DES implantation for DES restenosis lesions, and serial clinical and angiographic outcomes with a high follow-up rate were obtained. Second, the choice of a DES was made by the physician, which may have led to a possible selection bias. Finally, we did not perform 
Conclusions
Late restenosis occurs after both first DES implantation and second DES implantation for DES restenosis.
